Shares of telehealth facilitator, drug distributor, and GLP-1 provider Hims & Hers Health Inc. (NYSE: HIMS ) have been on a rollercoaster, especially after retail investors have become much more drawn to this stock thanHi! I'm a passionate investor who has been researching publically traded companies for over 6 years. My primary focus is on identifying great businesses at reasonable prices and holding them for the long term but I also dive into trend following strategies from time to time. While I have a sl ...

RALEIGH, N.C., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, Inc. today announced a collaboration with Hims & Hers™, one of the largest digital health platforms for men, to make KYZATREX®, an FDA-approved oral testosterone replacement therapy for adult men with low or no testosterone levels due to certain medical conditions, available to patients through the Hims & Hers platform in the coming months. This marks the first time Hims & Hers will offer an FDA-approved oral testosterone therapy, und ...

TRENDING: See Nvidia's Growing Appetite For Startup Investments Hims stock popped Wednesday after the telemedicine giant announced its long-awaited foray into offering testosterone replacement therapy. The announcement was highly anticipated given Hims & Hers Health (HIMS) has long discussed its plan to launch a testosterone replacement therapy, or TRT. There will be four options, offered in partnership with privately held Marius Pharmaceuticals. Pricing has yet to be outlined, but will likely run in the ra ...

周三，Hims&Hers Health(HIMS.US)股价走高，截至发稿，该股涨超7%，报51.39美元。消息面上，该 公司宣布，2026年将通过与睾酮疗法创新领军企业Marius Pharmaceuticals合作，在其平台上独家推出一 款口服睾酮药物KYZATREX。这款药物已经获得美国食品药品监督管理局批准，无需注射，使用更加 便捷。据临床数据，KYZATREX可使高达96%的男性恢复正常睾酮水平，同时将"游离睾酮"翻倍提升。 游离睾酮被认为与精力、驱动力和身体表现密切相关，而该药物在提升疗效的同时保持了较低的不良反 应率。 ...

智通财经APP获悉，周三，Hims & Hers Health(HIMS.US)股价走高，截至发稿，该股涨超7%，报51.39 美元。消息面上，该公司宣布，2026年将通过与睾酮疗法创新领军企业Marius Pharmaceuticals合作，在 其平台上独家推出一款口服睾酮药物KYZATREX®。这款药物已经获得美国食品药品监督管理局批 准，无需注射，使用更加便捷。据临床数据，KYZATREX®可使高达96%的男性恢复正常睾酮水平，同 时将"游离睾酮"翻倍提升。游离睾酮被认为与精力、驱动力和身体表现密切相关，而该药物在提升疗效 的同时保持了较低的不良反应率。 ...

Hims & Hers Health Inc. HIMS launched a new category in men’s health on Wednesday, offering access to affordable and personalized treatment plans for low testosterone.An estimated 20 million men in the U.S. struggle with low testosterone.Bloomberg earlier reported the update. The telehealth company's latest move comes as its weight-loss drug sales have slowed, impacting its stock performance in recent months. The new offerings aim to bolster its core sexual health services and tap into an underserved market ...

公司表现与投资观点 - 公司股票表现相对平淡 为积累提供更多时间 [1] - 公司在传统系统不足的领域蓬勃发展 提供谨慎的数字优先访问 [1] 投资策略与方法论 - 投资风格聚焦于爆发前的高潜力赢家 关注不对称机会 上行潜力至少2-3倍超过下行风险 [1] - 利用市场低效和逆向洞察 最大化长期复合并保护资本免受损害 [1] - 投资期限为4-5年 能够抵御波动 通过耐心、纪律和智能资本配置推动超额回报 [1] 公司领导力与管理 - 管理层拥有扩展业务的可验证记录 [1] - 智能资本配置和内部所有权 [1] - 持续收入增长和可信指导 [1] 市场地位与竞争优势 - 强大的技术护城河和先发优势 [1] - 推动指数级增长的网络效应 [1] - 在高增长行业中的市场渗透 [1] 财务状况与风险管理 - 可持续收入增长与高效现金流 [1] - 强劲的资产负债表和长期生存跑道 [1] - 避免过度稀释和财务弱点 [1] 估值与风险回报 - 收入倍数与同行和DCF模型比较 [1] - 机构支持和市场情绪分析 [1] - 确保下行保护与巨大上行潜力 [1] 投资组合构建 - 核心头寸占50-70% 高信心稳定投资 [1] - 成长型投资占20-40% 高风险高回报机会 [1] - 投机性投资占5-10% 具有巨大潜力的颠覆性投资 [1]

Hims & Hers Health said on Wednesday it is launching a new category in men's health, offering access to personalized treatment plans for low testosterone. ...

Hims & Hers Health is launching treatments for low testosterone on its telehealth platform, venturing deeper into a category often marred by stigma, according to its chief executive. ...

  GRANDE PRAIRIE, ALBERTA (September 10, 2025) – TheNewswire - ANGKOR RESOURCES CORP. (TSXV: ANK) (“ANGKOR” OR “THE COMPANY”) announces its subsidiary, EnerCam Resources Co. Ltd. (Cambodia) (“EnerCam”) has received approval  from government authorities of Ministry of Mines and Energy for an additional 220 square kilometers added within the Block VIII boundaries, referred to as the Mussel Basin.  With the added area, Block VIII now is 4277 square kilometers in size, having removed all parks and protected ar ...